Background:
Localized drug delivery to the respiratory system has become an increasingly successful and essential treatment strategy for several pulmonary diseases, including asthma, chronic abstractive disease, pneumonia, bronchitis, and cystic fibrosis. The rising incidence
of respiratory diseases is a significant factor driving the worldwide market for respiratory inhaler
devices.
Objective:
The objective of this article is to present various aspects of pharmaceutical aerosols,
including their types, components, fundamentals, in-process and finished product quality control
tests based on pharmacopeial standards and specifications, and commercial utility considering the
pharmaceutical aerosol dosage forms that have been patented from 2000 to 2020, along with a list
of marketed pharmaceutical products.
Method:
Aerosol, collectively referred to as a pressurized device, operates by triggering an appropriate valve system with a continuous or metered dosage of tiny mist spray. It is used not only
in the treatment of asthma and chronic obstructive pulmonary disease but also in the treatment of
cancer, diabetes, migraine, angina pectoris, acute lung injury, bone disorders, tuberculosis, and
many more. A multitude of different variables, including types and properties of propellants, active substances, containers, valves, actuators, spray patterns, valve crimping efficiency, and particle size of the aerosols, influence the therapeutic effectiveness of pharmaceutical aerosols.
Conclusion:
Based on the current findings, distinct characteristics such as the elimination of firstpass metabolism, quick drug absorption, ease of therapy termination, as well as a larger surface
area have attributed to the success of pharmaceutical aerosols.
Mechanisms of Pharmaceutical Aerosol Deposition in the Respiratory Tract
